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Abstract
Achieving malaria elimination requires targeting the human reservoir of infection, including those
with asymptomatic infection. Smear-positive asymptomatic infections detectable by microscopy
are an important reservoir because they often persist for months and harbor gametocytes, the
parasite stage infectious to mosquitoes. However, many asymptomatic infections are
submicroscopic and can only be detected by molecular methods. While there is some evidence that
persons with submicroscopic malaria can infect mosquitoes, transmission is much less likely to
occur at submicroscopic gametocyte levels. As malaria elimination programs pursue mass
screening and treatment of asymptomatic individuals, further research should strive to define the
degree to which submicroscopic malaria contributes to the infectious reservoir, and in turn, what
diagnostic detection threshold is needed to effectively interrupt transmission.
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Active surveillance targeting asymptomatic malaria for elimination
Over the past 5–10 years, increased international funding, political will, and a new
generation of malaria diagnostic and treatment tools has reignited efforts to achieve malaria
elimination. As of 2012, 34 of the 99 countries where malaria is endemic have adopted
strategies to become malaria free within the next two decades [1]. At the heart of these
strategies is a shift in focus from early diagnosis and treatment of those who are
symptomatic, to active surveillance for and treatment of every case, including those who are
asymptomatic [2,3].
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Asymptomatic malaria is often not defined rigorously, but generally refers to a person
harboring blood-stage malaria parasites who has not experienced fever or other symptoms
that would lead the individual to seek treatment. In most malaria endemic settings,
asymptomatic infections outnumber symptomatic infections [4,5,6]. It follows that the
success of elimination strategies relies on the ability to find and treat the asymptomatic
reservoir.
However, the lack of rigorous definitions for asymptomatic malaria has clouded research
supporting this goal [7,4]. Parasitemia in an asymptomatic infection can be visible by blood
smear, or submicroscopic and only detectable by molecular methods. The increasing use of
methods that detect parasite DNA, including PCR and Loop-mediated Isothermal
Amplification (LAMP), has uncovered large numbers of asymptomatic persons with
submicroscopic malaria. It is generally assumed that this translates into a greatly expanded
infectious reservoir. But most studies on the reservoir potential of asymptomatics have been
done on microscopically patent asymptomatics. Accordingly, the role of submicroscopic
malaria in ongoing transmission in most settings is unclear.
Below, we examine different lines of research to address the question of whether those with
submicroscopic malaria contribute substantially to transmission. We highlight the
heterogeneity of the asymptomatic malaria reservoir, what mosquito studies have shown
about determinants of human-to-mosquito infectivity, the limited studies on the infectivity
potential of submicroscopic malaria, and the lack of data available from ongoing elimination
efforts.
A better understanding of role of submicroscopic malaria as part of the transmission
reservoir can shape how active surveillance is used to pursue malaria elimination. For
example, recent mass screening and treatment efforts have used rapid diagnostic tests
(RDTs) with detection limits similar to microscopy (~200 parasites/μl) to find and treat
asymptomatic cases [8]. When these efforts failed to curb subsequent malaria transmission,
it has been suggested that more sensitive molecular diagnostics need to be deployed [9,10].
Along these lines, a recent consensus document by the Malaria Eradication Research
Agenda (malERA) consultative group suggests that any parasitemia, no matter how small,
represents potential for transmission and therefore is a threat to malaria elimination efforts
[11]. We propose that pursuit of the most sensitive diagnostic may be premature. Knowledge
gaps are highlighted and recommendations made for further research to better understand
how best to deploy active surveillance methods in the pursuit of malaria elimination.
The asymptomatic reservoir is heterogeneous in terms of persistence and
gametocyte carriage
The importance of asymptomatic malaria as a reservoir rests on two key characteristics:
duration of infection and gametocyte density. Gametocytes are the sexual stage of the
parasite produced in infected human hosts which must be ingested by mosquitoes for
transmission to occur. Infections persisting for long periods of time means more
opportunities for a malarious person to infect biting mosquitoes, especially since
gametocytes tend to appear late in P. falciparum infection, on the order of 7–15 days after
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the first appearance of parasites in the blood [12]. Infections with higher gametocyte
densities are generally more infectious. Persistence of infection and prevalent gametocyte
carriage have long been observed among those with asymptomatic malaria in moderate to
high transmission settings in Africa. However, the asymptomatic reservoir in low
transmission settings is more heterogeneous and does not necessarily share these same
attributes.
In moderate to high transmission settings in Africa, it is common for asymptomatic
individuals to harbor microscopically patent (smear-positive) infections that last from weeks
to months [13,14] (Box 1). This phenomenon has been explained by a form of acquired
immunity that keeps parasitemia and symptoms in check without achieving complete
clearance [15]. Longitudinal genotyping of a Ghanian cohort has confirmed that these are
persistent infections of the same strains, rather than representing frequent reinfection, and
that they persist an average of 194 days [16]. While gametocytes were not measured in this
study, it is likely that these individuals were gametocytemic and thus infectious during much
of this time. In fact, asymptomatic microscopically patent infections may be more infectious
than clinical malaria. An association between lack of fever and gametocyte carriage has
been observed in smear-positive children in the Gambia and Nigeria [17,18]. Additional
evidence of the gametocyte production potential of microscopically patent asymptomatics
comes from two longitudinal studies in the Gambia and Kenya of untreated asymptomatic
infections. [19,20]. In these studies, 11–25% were gametocytemic at baseline, while
approximately 15–20% of microscopically patent asymptomatics without baseline
gametocytes became gametocytemic over four weeks. Thus, evidence from a number of
studies show that asymptomatic individuals with patent parasitemia are important reservoirs,
but none of them looked for submicroscopic infections.
Box 1
Heterogeneity of the asymptomatic malaria reservoir
The asymptomatic reservoir is composed of those with submicroscopic and microscopic
parasitemia. In both high (Figure IA) and low (Figure IB) transmission settings,
asymptomatic infections far outnumber symptomatic infections [4,5,6]. However, in low
transmission settings, most of the asymptomatic reservoir is composed of submicroscopic
parasitemia [4,21,5,22,23]. The relative contribution of submicroscopic and microscopic
parasitemia to transmission is unknown.
The asymptomatic reservoir’s contribution to malaria transmission is mediated by the
duration of infection, incidence of gametocyte carriage, and ultimately determined by
mosquito infectivity. These and other factors are likely to differ in low vs. high
transmission settings and in microscopic vs. submicroscopic parasitemia within these
settings (Table I).
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The contribution of microscopic vs. submicroscopic
infections to the asymptomatic malaria reservoir
High transmission setting Low transmission setting
Microscopic Submicroscopic Refs Microscopic Submicroscopic Refs
Persistence of infectiona Days to months [13,14,16] Days to weeks?b [26,27,28]
Gametocyte carriagec 15–50% ? [19,20,37,54] 1–50%b ? [52,65,29]
Mosquito infectivityd 10–75% ? [53,54] 3–10% ? [52,53]




Studies cited included P. vivax in addition to P. falciparum
c
gametocytes visible by microscopy
d
the proportion of persons infective to mosquitoes
e
the proportion of mosquitoes infected within a study population
The situation in non-African low transmission settings is more complicated. First, in contrast
to many African settings, the majority of asymptomatic malaria infections in areas such as
the Amazon and Southeast Asia are submicroscopic [4,21,5,22,23] (Box 1). Second, outside
of Africa, Plasmodium vivax is the most prevalent malaria species and malarious areas are
often co-endemic for P. falciparum and P. vivax, with P. vivax presenting unique challenges
to elimination (Box 2). Finally, with lower levels of transmission, acquired immunity is
expected to be lower. So at any given time point, an individual may be more likely to be
asymptomatic because he/she is either in the process of resolving parasitemia due to
treatment or might be in the process of developing a symptomatic infection [7,4,24,25].
Each of these major differences means that the asymptomatic reservoir may vary in different
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settings with regards to persistence, gametocyte carriage, and hence mosquito infectivity and
transmission potential.
Box 2
P. vivax hypnozoites represent an invisible reservoir and obstacle to
elimination efforts
The unique biological characteristics of Plasmodium vivax present even more challenges
for elimination [74,1]. Perhaps most important is its propensity to cause relapse. After a
P. vivax-infected mosquito bites a person, a portion of parasites establish a latent liver-
stage infection in the form of hypnozoites. Hypnozoites can remain dormant in the liver
for weeks or years until unknown triggers cause their reactivation and entry into the
bloodstream, where they cause clinical relapse [75]. Remarkably, a single mosquito bite
can lead to multiple malaria relapses even when a person has been adequately treated
with drugs that clear blood-stage parasites.
Several other biologic characteristics of P. vivax make it is plausible that in low
transmission settings, many asymptomatic individuals infected with P. vivax are
gametocytemic and contribute to transmission in a meaningful way. Perhaps due to
frequent relapse, most studies show that immunity to P. vivax is typically acquired earlier
in life than P. falciparum in settings where the species are co-endemic [76]. It follows
that asymptomatic P. vivax infection is relatively common even in low transmission
settings [4]. Additionally, in contrast to P. falciparum gametocytes, P. vivax gametocytes
arise early in infection and accompany the majority of symptomatic infections, though
they have a relatively short lifespan, on the order of 3 days [32,12]. As with P.
falciparum, submicroscopic gametocyte densities have also been shown to lead to
mosquito infection [42].
However, the converse conclusion - that mass screening and treatment efforts can
interrupt P. vivax transmission - is problematic. This is because of the hidden P. vivax
hypnozoite reservoir. Excluding the pre-patent liver stage of infection, the P. falciparum
asymptomatic reservoir can be characterized as made up of those who are either smear-
positive or submicroscopic, while the P. vivax asymptomatic reservoir contains an
additional fraction of infected persons without bloodstream parasites but with dormant
liver-stage hypnozoites. These persons harboring hypnozoites with potential for relapse
cannot be identified by any current diagnostic tests. Thus, one-time or even periodic mass
screen-and-treat efforts will only detect infections that have coincidentally reactivated at
the time of screening. The size of the hypnozoite reservoir is unknown in all but the
most-studied settings, but is likely to be substantial [77]. Perhaps this is why the few
examples of successful interruption of P. vivax transmission have been associated with
Mass Drug Administration (MDA) [78,79] rather than screen and treatment efforts.
Research recommendations
Ultrasensitive molecular tests might incrementally detect a larger proportion of
submicroscopic and potentially gametocytemic P. vivax infections within a population,
but their use is perhaps inconsequential for achieving elimination in the face of a much
Lin et al. Page 5






















larger hidden hypnozoite reservoir that remains intact. Lines of research that evaluate
frequent periodic screening, replace mass screening with MDA with the aid of point-of-
care G6PD testing, or uncover triggers of relapse can inform active surveillance
strategies for P. vivax. However, for most areas where P. vivax is endemic, development
of a diagnostic test that can detect latent hypnozoite infections in conjunction with a safe
single-dose anti-hypnozoite drug and are probably needed in order to make elimination a
realistic goal [11,80,74].
The duration of infection among asymptomatics in low transmission settings remains elusive
(Box 1). The very limited evidence suggests that a minority can persist for several weeks,
but the majority spontaneously clear. In Brazil, 16 submicroscopic PCR-positive persons
with asymptomatic Plasmodium vivax infection were followed for 30 days; three-quarters
were PCR-negative at 2 weeks, while the remaining four remained PCR-positive at 30 days,
with none developing symptoms [26]. In serial cross-sectional studies conducted in
Colombia and Peru, roughly half of smear-positive asymptomatic infections spontaneously
cleared within 14 days in Colombia (13/24) and within 7 days in Peru (16/30) [27,28,29]. As
for the rest, the majority remained asymptomatic at follow-up, with half of those in the Peru
study showing decreased parasitemia at day 7, and 25% of those in the Colombian study
remaining parasitemic at day 14. Overall, the duration of untreated submicroscopic
infections in low-transmission areas seems to be much shorter than asymptomatic P.
falciparum infections in Africa.
Even less is known about gametocyte carriage among asymptomatic infections in low
transmission settings. One study in Peru limited to smear-positive malaria found that an
impressive 50% of P. falciparum and 22% P. vivax infections identified by active case
detection harbored gametocytes [29]. However this was in the context of an overall malaria
prevalence of 63% in the at-risk zones that were targeted. Otherwise, studies of gametocyte
carriage have mostly been limited to those enrolled in clinical trials. Studies in Thailand
have found that the greatest risk factor for P. falciparum gametocyte carriage was visible
gametocytemia at admission [30], present in just 2.4% of patients. Meanwhile, the average
duration of gametocytemia post-treatment in Thailand is significantly shorter than in the
Gambia [31]. For P. vivax patients in Thailand and Indonesia, gametocyte carriage mirrored
asexual parasitemia, with high asexual parasitemia associated with increased risk of
gametocytemia during follow-up [32]. These studies perhaps indirectly suggest that
submicroscopic asymptomatic malaria does not have the same infectious potential as
asymptomatic malaria in Africa.
Studies of mosquito infectivity indicate a gametocyte threshold detectable
by microscopy
Gametocytes serve as an imperfect surrogate marker of transmission potential. Experimental
studies whereby mosquitoes are fed blood-stage parasites, either by direct skin feeding or
via a membrane feeding apparatus, and subsequently dissected to look for malaria parasites
(oocysts in the mosquito midgut), represent a more direct way for assessing human-to-
mosquito infectious potential [33,34,35,36].
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Individuals with higher gametocytemia are generally more infectious to mosquitoes than
those with low gametocytemia. While children in Africa without smear-detectable
gametocytes are capable of infecting mosquitoes, infections occur in only a small minority
of mosquitoes [37,38]. In contrast, evidence from many studies suggests a threshold of ~100
gametocytes/μL, above which individual more consistently achieved infection in the
majority of mosquitoes, and cause mosquito infections with higher oocyst burdens[39,40]
(Figure 2). More recent data based on modeling of mosquito membrane feeding studies in
Burkina Faso and Kenya similarly found that while 4% of mosquitoes are infected at 1
gametocyte/μL, this low infectivity rate does not increase meaningfully until ~200
gametocytes/μL are present [41] (Figure 2).
Comparable studies for P. vivax are few in number. While they suggest a positive
correlation between gametocyte density and frequency of mosquito infection, an appreciable
gametocyte threshold above which infection is likely has not been defined [35,42,43].
Because the density of gametocytes relative to asexual parasites in P. falciparum infection is
usually low fewer than 5% in most settings [44] – a gametocyte threshold of ~100
gametocytes/μL roughly translates into an overall parasitemia of 2000 parasites/μL, well into
the range of parasitemia detectable by microscopy. There may be parasite and host factors
beyond gametocyte density that are important determinants of human-to-mosquito
infectivity [12,45,46,47], and membrane feeding assays may still be an imperfect way of
measuring human infectiousness to mosquitoes [48). Overall, these data argue that
submicroscopic infections may not contribute substantially to the reservoir.
The potential role of submicroscopic malaria in transmission has only been
indirectly studied in high transmission settings with prevalent gametocyte
carriage
Should all parasitemic individuals be considered current or future gametocytes producers
and, by implication, treated [12,49]? Studies supporting this rationale have been largely
confined to children in Africa [37,38], a group where gametocyte carriage is expected to be
more prevalent. Further, while microscopically positive gametocytemic individuals are
clearly infectious to mosquitoes, some studies highlighting the infectious potential of
submicroscopic gametocytemia can be hard to interpret because they do not specify whether
such subjects also had submicroscopic malaria (i.e., they could have had detectable asexual
stages).
Among a random sample of 80 children in Burkina Faso, roughly twice as many of those
with microscopically detectable gametocytes were infectious to mosquitoes compared to
those with gametocytes detectable only by molecular methods: 68% with smear-detectable
gametocytes infected on average 13% of mosquitoes, while 32% with submicroscopic
gametocytes infected on average 2.3% of mosquitoes [37]. Based on these numbers, it was
estimated that those with submicroscopic gametocytes contributed to 24.2% of overall
transmission because of their greater prevalence in the population. However, <20% of
children in this study had submicroscopic malaria, so the majority with submicroscopic
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gametocytemia likely still had asexual parasites visible by smear. Another study in western
Kenya also found that submicroscopic gametocytemia frequently resulted in mosquito
infection [38]. However, the study recruited children who were 14 days post-treatment,
mostly with SP-containing regimens, which have been associated with increased post-
treatment gametocytemia [50,51,31].
Human-to-mosquito infectivity studies among asymptomatics in Thailand also found
persons harboring submicroscopic gametocytemia that were infectious to mosquitoes, but
these were among microscopically patent infections. Village-wide screening by microscopy
in western Thailand resulted in 3.3% of persons infected with P. falciparum by microscopy,
80% of whom were asymptomatic [52]. Among the 51 infected persons in whom
gametocytes were not visible, 5 (9.8%) still infected mosquitoes, yielding low oocyst
burdens (average 1.2 oocysts/mosquito). Meanwhile, 13.5% of the P. vivax patients without
smear detectable gametocytes also infected mosquitoes. Overall, 10% of identified P.
falciparum infections transmitted their infection to mosquitoes in a membrane-feeding
assay, a rate similar to that seen in asymptomatics found by active surveillance in two
villages in Cameroon (9–13%) [53], but much lower than that observed in a village sample
in Burkina Faso (>50%) and treated children in western Kenya (62%) [54,38]. These studies
suggest that the underlying gametocyte prevalence in different settings can vary widely and
has an impact on the size of the infectious reservoir [12,31].
Should PCR be used to screen for the transmission reservoir? Epidemiologic data pertaining
directly to this question are scarce. In one study in the Brazilian Amazon, 15 asymptomatic
carriers (11 P. vivax, 3 P. falciparum, 1 mixed P. falciparum/vivax) detected in a mass
survey who were microscopy-negative but PCR positive were recruited for mosquito feeding
experiments two months after PCR diagnosis. Of 294 mosquitoes fed on their blood by both
direct and membrane feeding, two mosquitoes became infected with one P. vivax oocyst
each, yielding an infection rate of 0.7% [55]. Comparing this to a mosquito infection rate of
22% among 17 symptomatic carriers with microscopically detectable parasitemia in the
same study, yields an approximately 300 fold difference in infectivity between
submicroscopic asymptomatics and microscopic symptomatics in this setting.
Further epidemiologic data gleaned from three human-to-mosquito infectivity studies was
recently cited to compare mosquito infectivity between submicroscopic and microscopic
asymptomatics. These showed between a 4 and 16-fold difference in % mosquitoes infected
among submicroscopic vs. slide-positive P. falciparum infections [56]. However, one of
these studies involved African-American malariotherapy patients with neurosyphilis who
were partially treated [57], another represents unpublished data from Burkina Faso, and in
the third study from South Carolina in 1948 [58], the prevalence of submicroscopic carriers
had to be estimated. All three studies appear to be drawn from populations where the
underlying gametocyte prevalence is high: slide detectable gametocyte prevalence was
≥68% in the malariaotherapy study and 64% in the South Carolina study [57,58].
Gametocyte prevalence in areas where malaria is now hypoendemic is expected to be much
lower. Thus, these 4 to 16-fold infectivity ratios are only rough estimates. These estimates
were used to suggest that submicroscopic carriers are the source of 20–50% of all human-to-
mosquito transmissions when transmission reaches very low levels [56]. This conclusion,
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while based on the best available evidence, underscores the need for more epidemiologic
data, especially from low transmission settings where malaria elimination efforts are
underway.
Sparse data exist from elimination efforts using active surveillance to guide
practice
As countries pursue malaria elimination, interventions ranging from focal or mass screening
and treatment to mass drug administration to targeted populations are being tried [3].
Reactive case detection, whereby households within an established radius surrounding a
symptomatic positive index case are screened, is also increasingly being used as a strategy
that bridges passive and active surveillance [59,60,61]. Many of these efforts are applying
molecular methods to find and treat asymptomatic infections [23,62,63,64]. But we found
only two attempts to measure gametocytes in such studies. In a school and population-based
survey in the Melanesian Islands where an overall malaria point prevalence of 2–3% was
found by both microscopy and PCR, gametocytes were detected in 15% of the P. falciparum
positives and 4% of the P. vivax positives [65]. In northwest Thailand, PCR of 475 persons
in two villages as part of a mass screening revealed eight cases with low density parasitemia
later confirmed by expert microscopists. None of these carried gametocytes visible by
smear, but submicroscopic gametocytes were not measured [66]. Because infected persons
are treated, the duration of these submicroscopic cases is also unknown. The possibility
exists that the submicroscopic infections found by such surveillance efforts might not
contribute significantly to the transmission reservoir [3].
Research strategies
Because of the logistical difficulties of studying asymptomatic infections, much of what is
known about asymptomatic malaria in African settings has been extrapolated to settings
with much lower transmission where the asymptomatic reservoir mostly consists of those
with submicroscopic malaria. Studies of duration of infection, submicroscopic gametocyte
carriage, and gametocyte production potential need to be carried out in submicroscopic
infections in low transmission settings where elimination is being considered (Box 3). This
can be done, either by retrospective molecular analysis of prior cohort studies where only
microscopy was used, or prospectively, in the context of cohort studies and national surveys,
in which microscopy-negative but PCR-positive subjects are followed and not treated unless
they become symptomatic or develop patent parasitemia. These studies are made more
feasible by available methods to measure submicroscopic gametocytemia from blood spots
collected for PCR [67,68,69,70,71] but require longitudinal follow up which can be
challenging.
Box 3
Outstanding questions and possible strategies to answer them
Research Question Possible Study Designs
Submicroscopic parasitemia
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Research Question Possible Study Designs
 What proportion of untreated/unrecognized
submicroscopic infections persist asymptomatically?
Retrospective molecular analysis of prior cohort
studies where only microscopy was used.
 What proportion go on to become microscopically
patent and/or symptomatic?
 How often do treated patients develop subsequent
submicroscopic parasitemia?
Retrospective molecular analysis of therapeutic
efficacy studies.
Transmission potential of submicroscopic infections
 What proportion of submicroscopic infections
harbor or produce gametocytes, and at what density?
Prospective molecular analysis incorporated into
cohort studies or national surveys.
 Besides gametocyte density, what parasite or
human host factors affect human-to-mosquito
infectivity?
In vitro membrane feeding assays
 How commonly does submicroscopic vs.
microscopic malaria in asymptomatics successfully
infect mosquitoes? How does this vary in different
transmission settings and in different mosquito
vectors?
Vectorial capacity studies, estimates of
Entomological Inoculation Rate (EIR), mosquito
membrane feeding studies in vitro and from
patients in surveys and/or cohorts
Diagnostic tests to detect submicroscopic parasitemia and estimate transmissibility
 How sensitive does a diagnostic test need to be to
identify all those in the infectious reservoir?
Comparative analysis of diagnostic tests
incorporated into cohort studies and mass surveys,
paired with malaria seroprevalence surveys
 How large is the hypnozoite reservoir in P. vivax
endemic areas, and how can it be measured?
Studies to identify surrogate markers of latent P.
vivax infection
Going one step further, human-to-mosquito infectivity studies can provide more direct
information about the transmission potential of submicroscopic infections (Box 3). Ideally,
serial mosquito membrane feeding studies using local mosquito vectors would be conducted
in those with asymptomatic submicroscopic malaria identified by current mass screening
and treatment efforts. While challenging and tedious, these would more directly measure the
potential impact that submicroscopic cases uncovered by active surveillance have on
transmission. Since such studies still do not measure mosquito-to-human transmission or
overall malaria incidence, cluster randomized trials of different interventions, for example
mass screening and treatment vs. mass drug administration vs. vector control, remain
important [72]. Incorporating different types of molecular diagnostics (RDT, PCR, and
LAMP) into such studies would allow better definition of a diagnostic threshold for
elimination below which transmission is unlikely, a practical goal that could guide allocation
of resources for diagnostics in malaria elimination programs.
The policy implications are important: if individuals found by active surveillance to have
submicroscopic malaria turn out to have minimal transmission potential, perhaps
ultrasensitive PCR methods are not as important as an emphasis on better coverage and
follow up of targeted populations. If partially treated or pre-symptomatic persons make up a
significant part of the asymptomatic reservoir, intensifying malaria treatment efforts to
involve periodic follow up post-treatment as well as enhancing early detection might be
more cost-effective than screening large populations.
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As resources are allotted to elimination efforts, further research is critical to better
characterize the asymptomatic reservoir in settings where elimination is being pursued and
the factors that may or may not make submicroscopic infections important for continuing
transmission. In particular, a key operational question is, “how sensitive does a diagnostic
test need to be to identify all of those who make up the infectious reservoir?” Because a
gametocyte-mosquito infectivity threshold has been established for P. falciparum in African
settings, this can act as a guide. Nevertheless, determining the gametocyte carriage potential
of individuals followed without treatment is also key, especially for those with
submicroscopic parasitemia. In regards to infection with P. vivax, the present inventory of
tools is inadequate to achieve elimination without a diagnostic marker for latent hypnozoite
infection or introduction of a universally safe antimalarial that can clear hypnozoites.
Presently, the lack of evidence for or against a substantive role of submicroscopic malaria
for transmission makes the ethics of treating asymptomatic and submicroscopic parasitemia
unclear and dependent on the risk-benefit ratios of the treatment and/or prevention strategies
being implemented. Untreated individuals may go on to develop clinical disease at rates that
are currently unpredictable and infect others in their households or communities.
Alternatively, infection could clear despite treatment that might cause adverse effects in
patients. If the treatment is ineffective, they may continue to harbor persistent, increasingly
drug-resistant parasites post treatment. The spread of infection, while thought by some to be
from a widespread reservoir of asymptomatic individuals, may in fact be limited to only a
relatively small pool of patients with microscopically patent infection. The sporadic and
focal nature of malaria transmission argues for the latter hypothesis. However, even if
transmission is focal, and limited to a few carriers, the potential beneficial effects of mass
treatment to provide prophylaxis and disrupt transmission must be considered carefully [73].
Longitudinal studies that incorporate molecular analyses and mosquito membrane feeding
techniques will help tease out some of these outcomes and contribute substantially to our
understanding of how best to target the asymptomatic malaria reservoir.
Acknowledgments
This work was supported by an American Society of Tropical Medicine & Hygiene/Burroughs Wellcome
Postdoctoral Fellowship in Tropical Infectious Disease to J.T.L., the U.S. Department of Defense Global Emerging
Infections Surveillance and Response System Program, and National Institute of Allergy and Infectious Diseases
(NIH grant R56AI097609 to S.R.M). The views expressed in this paper are those of the authors and do not
represent the official position of the U.S. Department of Defense.
References
1. Cotter C, et al. The changing epidemiology of malaria elimination: new strategies for new
challenges. Lancet. 2013; 382:900–911. [PubMed: 23594387]
2. Mendis K, et al. From malaria control to eradication: The WHO perspective. Trop Med Int Health.
2009; 14:802–809. [PubMed: 19497083]
3. Sturrock HJW, et al. Targeting asymptomatic malaria infections: active surveillance in control and
elimination. PLoS Med. 2013; 10:e1001467. [PubMed: 23853551]
4. Lindblade KA, et al. The silent threat: asymptomatic parasitemia and malaria transmission. Expert
Rev Anti Infect Ther. 2013; 11:623–639. [PubMed: 23750733]
Lin et al. Page 11






















5. Alves FP, et al. High prevalence of asymptomatic Plasmodium vivax and Plasmodium falciparum
infections in native Amazonian populations. Am J Trop Med Hyg. 2002; 66:641–648. [PubMed:
12224567]
6. Pinto J, et al. Malaria in São Tomé and Príncipe: parasite prevalences and vector densities. Acta
Trop. 2000; 76:185–193. [PubMed: 10936578]
7. Laishram DD, et al. The complexities of malaria disease manifestations with a focus on
asymptomatic malaria. Malar J. 2012; 11:29. [PubMed: 22289302]
8. Sutcliffe CG, et al. Reduced risk of malaria parasitemia following household screening and
treatment: a cross-sectional and longitudinal cohort study. PLoS ONE. 2012; 7:e31396. [PubMed:
22319629]
9. Tiono AB, et al. A controlled, parallel, cluster-randomized trial of community-wide screening and
treatment of asymptomatic carriers of Plasmodium falciparum in Burkina Faso. Malar J. 2013;
12:79. [PubMed: 23442748]
10. Hoyer S, et al. Focused Screening and Treatment (FSAT): a PCR-based strategy to detect malaria
parasite carriers and contain drug resistant P. falciparum, Pailin, Cambodia. PLoS ONE. 2012;
7:e45797. [PubMed: 23049687]
11. malERA Consultative Group on Diagnoses and Diagnostics. A research agenda for malaria
eradication: diagnoses and diagnostics. PLoS Med. 2011; 8:e1000396. [PubMed: 21311583]
12. Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium
vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev. 2011;
24:377–410. [PubMed: 21482730]
13. Males S, et al. Long-term asymptomatic carriage of Plasmodium falciparum protects from malaria
attacks: a prospective study among Senegalese children. Clin Infect Dis. 2008; 46:516–522.
[PubMed: 18199040]
14. Bottius E, et al. Malaria: even more chronic in nature than previously thought; evidence for
subpatent parasitaemia detectable by the polymerase chain reaction. Trans R Soc Trop Med Hyg.
1996; 90:15–19. [PubMed: 8730301]
15. Doolan DL, et al. Acquired immunity to malaria. Clin Microbiol Rev. 2009; 22:13–36. [PubMed:
19136431]
16. Felger I, et al. The dynamics of natural Plasmodium falciparum infections. PLoS ONE. 2012;
7:e45542. [PubMed: 23029082]
17. Von Seidlein L, et al. Risk factors for gametocyte carriage in Gambian children. Am J Trop Med
Hyg. 2001; 65:523–527. [PubMed: 11716108]
18. Sowunmi A, et al. Risk factors for gametocyte carriage in uncomplicated falciparum malaria in
children. Parasitology. 2004; 129:255–262. [PubMed: 15471001]
19. Dunyo S, et al. Gametocytaemia after drug treatment of asymptomatic Plasmodium falciparum.
PLoS Clin Trials. 2006; 1:e20. [PubMed: 17013431]
20. Bousema JT, et al. Plasmodium falciparum gametocyte carriage in asymptomatic children in
western Kenya. Malar J. 2004; 3:18. [PubMed: 15202944]
21. Okell LC, et al. Submicroscopic infection in Plasmodium falciparum-endemic populations: a
systematic review and meta-analysis. J Infect Dis. 2009; 200:1509–1517. [PubMed: 19848588]
22. Steenkeste N, et al. Sub-microscopic malaria cases and mixed malaria infection in a remote area of
high malaria endemicity in Rattanakiri province, Cambodia: implication for malaria elimination.
Malar J. 2010; 9:108. [PubMed: 20409349]
23. Harris I, et al. A large proportion of asymptomatic Plasmodium infections with low and sub-
microscopic parasite densities in the low transmission setting of Temotu Province, Solomon
Islands: challenges for malaria diagnostics in an elimination setting. Malar J. 2010; 9:254.
[PubMed: 20822506]
24. El-Sayed B, et al. A randomized open-label trial of artesunate- sulfadoxine-pyrimethamine with or
without primaquine for elimination of sub-microscopic P. falciparum parasitaemia and gametocyte
carriage in eastern Sudan. PLoS ONE. 2007; 2:e1311. [PubMed: 18074034]
25. da Silva-Nunes M, Ferreira MU. Clinical spectrum of uncomplicated malaria in semi-immune
Amazonians: beyond the ‘symptomatic’ vs ‘asymptomatic’ dichotomy. Memórias do Instituto
Oswaldo Cruz. 2007; 102:341–348. [PubMed: 17568940]
Lin et al. Page 12






















26. Camargo EP, et al. Symptomless Plasmodium vivax infections in native Amazonians. Lancet.
1999; 353:1415–1416. [PubMed: 10227233]
27. Cucunubá ZM, et al. Asymptomatic Plasmodium spp. infection in Tierralta, Colombia. Mem Inst
Oswaldo Cruz. 2008; 103:668–673. [PubMed: 19057816]
28. Cucunubá ZM, et al. Comparison of asymptomatic Plasmodium spp. infection in two malaria-
endemic Colombian locations. Trans R Soc Trop Med Hyg. 2013; 107:129–136. [PubMed:
23222954]
29. Branch O, et al. Clustered local transmission and asymptomatic Plasmodium falciparum and
Plasmodium vivax malaria infections in a recently emerged, hypoendemic Peruvian Amazon
community. Malaria Journal. 2005; 4:27. [PubMed: 15975146]
30. Price R, et al. Risk factors for gametocyte carriage in uncomplicated falciparum malaria. Am J
Trop Med Hyg. 1999; 60:1019–1023. [PubMed: 10403336]
31. Stepniewska K, et al. Plasmodium falciparum gametocyte dynamics in areas of different malaria
endemicity. Malar J. 2008; 7:249. [PubMed: 19055751]
32. Douglas NM, et al. Gametocyte Dynamics and the Role of Drugs in Reducing the Transmission
Potential of Plasmodium vivax. J Infect Dis. 2013; 208:801–812. [PubMed: 23766527]
33. Bousema T, et al. Mosquito feeding assays to determine the infectiousness of naturally infected
Plasmodium falciparum gametocyte carriers. PLoS ONE. 2012; 7:e42821. (2012). [PubMed:
22936993]
34. Stone WJR, et al. The relevance and applicability of oocyst prevalence as a read-out for mosquito
feeding assays. Sci Rep. 2013; 3:3418. [PubMed: 24301557]
35. Sattabongkot J, et al. Comparison of artificial membrane feeding with direct skin feeding to
estimate the infectiousness of Plasmodium vivax gametocyte carriers to mosquitoes. Am J Trop
Med Hyg. 2003; 69:529–535. [PubMed: 14695091]
36. Gamage-Mendis AC, et al. Infectivity of Plasmodium vivax and P. falciparum to Anopheles
tessellatus; relationship between oocyst and sporozoite development. Trans R Soc Trop Med Hyg.
1993; 87:3–6. [PubMed: 8465388]
37. Ouédraogo AL, et al. Substantial contribution of submicroscopical Plasmodium falciparum
gametocyte carriage to the infectious reservoir in an area of seasonal transmission. PLoS ONE.
2009; 4:e8410. [PubMed: 20027314]
38. Schneider P, et al. Submicroscopic Plasmodium falciparum gametocyte densities frequently result
in mosquito infection. Am J Trop Med Hyg. 2007; 76:470–474. [PubMed: 17360869]
39. Carter, R.; Graves, PM. Gametocytes. In: Wernsorfer, WH.; McGregor, I., editors. Malaria:
Principles and Practice of Malariology. Churchill Livingstone; 1988. p. 253-305.
40. Bell AS, et al. Enhanced Transmission of Drug-Resistant Parasites to Mosquitoes following Drug
Treatment in Rodent Malaria. PLoS ONE. 2012; 7:e37172. [PubMed: 22701563]
41. Churcher TS, et al. Predicting mosquito infection from Plasmodium falciparum gametocyte density
and estimating the reservoir of infection. Elife. 2013; 2:e00626. [PubMed: 23705071]
42. Bharti AR, et al. Experimental infection of the neotropical malaria vector Anopheles darlingi by
human patient-derived Plasmodium vivax in the Peruvian Amazon. Am J Trop Med Hyg. 2006;
75:610–616. [PubMed: 17038681]
43. Sattabongkot J, et al. Plasmodium vivax: gametocyte infectivity of naturally infected Thai adults.
Parasitology. 1991; 102(Pt 1):27–31. [PubMed: 2038501]
44. Taylor LH, Read AF. Why so few transmission stages? Reproductive restraint by malaria parasites.
Parasitol Today. 1997; 13:135–140. [PubMed: 15275099]
45. Nwakanma D, et al. High gametocyte complexity and mosquito infectivity of Plasmodium
falciparum in the Gambia. Int J Parasitol. 2008; 38:219–227. [PubMed: 17709108]
46. Paul REL, et al. Aggregation in malaria parasites places limits on mosquito infection rates. Infect
Genet Evol. 2007; 7:577–586. [PubMed: 17521970]
47. McQueen PG, et al. Host immune constraints on malaria transmission: insights from population
biology of within-host parasites. Malar J. 2013; 12:206. [PubMed: 23767770]
Lin et al. Page 13






















48. Gouagna LC, et al. Comparison of field-based xenodiagnosis and direct membrane feeding assays
for evaluating host infectiousness to malaria vector Anopheles gambiae. Acta Trop. 2013; 130C:
131–139. [PubMed: 24262642]
49. Mosha JF, et al. Epidemiology of subpatent Plasmodium falciparum infection: implications for
detection of hotspots with imperfect diagnostics. Malar J. 2013; 12:221. [PubMed: 23815811]
50. Barnes KI, et al. Increased gametocytemia after treatment: an early parasitological indicator of
emerging sulfadoxine-pyrimethamine resistance in falciparum malaria. J Infect Dis. 2008;
197:1605–1613. [PubMed: 18471066]
51. Bousema JT, et al. Moderate effect of artemisinin-based combination therapy on transmission of
Plasmodium falciparum. J Infect Dis. 2006; 193:1151–1159. [PubMed: 16544256]
52. Coleman RE, et al. Infectivity of asymptomatic Plasmodium-infected human populations to
Anopheles dirus mosquitoes in western Thailand. J Med Entomol. 2004; 41:201–208. [PubMed:
15061279]
53. Bonnet S, et al. Estimation of malaria transmission from humans to mosquitoes in two
neighbouring villages in south Cameroon: evaluation and comparison of several indices. Trans R
Soc Trop Med Hyg. 2003; 97:53–59. [PubMed: 12886806]
54. Boudin C, et al. High human malarial infectivity to laboratory-bred Anopheles gambiae in a village
in Burkina Faso. Am J Trop Med Hyg. 1993; 48:700–706. [PubMed: 8517489]
55. Alves FP, et al. Asymptomatic carriers of Plasmodium spp. as infection source for malaria vector
mosquitoes in the Brazilian Amazon. J Med Entomol. 2005; 42:777–779. [PubMed: 16363160]
56. Okell LC, et al. Factors determining the occurrence of submicroscopic malaria infections and their
relevance for control. Nat Commun. 2012; 3:1237. [PubMed: 23212366]
57. Jeffert GM, Eyles DE. Infectivity to mosquitoes of Plasmodium falciparum as related to
gametocyte density and duration of infection. Am J Trop Med Hyg. 1955; 4:781–789. [PubMed:
13259002]
58. Young MD, Hardman NF. The infectivity of native malarias in South Carolina to Anopheles
quadrimaculatus. Am J Trop Med Hyg. 1948; 28:303–311. [PubMed: 18858032]
59. Rogawski ET, et al. Active case detection with pooled real-time PCR to eliminate malaria in Trat
province, Thailand. Am J Trop Med Hyg. 2012; 86:789–791. [PubMed: 22556075]
60. Sturrock HJW, et al. Reactive case detection for malaria elimination: real-life experience from an
ongoing program in Swaziland. PLoS ONE. 2013; 8:e63830. [PubMed: 23700437]
61. Littrell M, et al. Case investigation and reactive case detection for malaria elimination in northern
Senegal. Malar J. 2013; 12:331. [PubMed: 24044506]
62. Kritsiriwuthinan K, Ngrenngarmlert W. Molecular screening of Plasmodium infections among
migrant workers in Thailand. J Vector Borne Dis. 2011; 48:214–218. [PubMed: 22297283]
63. De AW, Gunasekera WMKT, et al. Usefulness of polymerase chain reaction to supplement field
microscopy in a pre-selected population with a high probability of malaria infections. Am J Trop
Med Hyg. 2011; 85:6–11. [PubMed: 21734117]
64. Atkinson JA, et al. Operational research to inform a sub-national surveillance intervention for
malaria elimination in Solomon Islands. Malar J. 2012; 11:101. [PubMed: 22462770]
65. Pacific Malaria Initiative Survey Group (PMISG) on behalf of the Ministries of Health of Vanuatu
and Solomon Islands. Malaria on isolated Melanesian islands prior to the initiation of malaria
elimination activities. Malar J. 2010; 9:218. [PubMed: 20659316]
66. Congpuong K, et al. Mass blood survey for malaria: pooling and real-time PCR combined with
expert microscopy in north-west Thailand. Malar J. 2012; 11:288. [PubMed: 22909399]
67. Babiker HA, Schneider P. Application of molecular methods for monitoring transmission stages of
malaria parasites. Biomed Mater. 2008; 3:034007. [PubMed: 18708712]
68. Mlambo G, et al. A filter paper method for the detection of Plasmodium falciparum gametocytes
by reverse transcription polymerase chain reaction. Am J Trop Med Hyg. 2008; 78:114–116.
[PubMed: 18187793]
69. Schneider P, et al. Quantification of Plasmodium falciparum gametocytes in differential stages of
development by quantitative nucleic acid sequence-based amplification. Mol Biochem Parasitol.
2004; 137:35–41. [PubMed: 15279949]
Lin et al. Page 14






















70. Buates S, et al. Development of a reverse transcription-loop-mediated isothermal amplification
(RT-LAMP) for clinical detection of Plasmodium falciparum gametocytes. Parasitol Int. 2010;
59:414–420. [PubMed: 20542143]
71. Wampfler R, et al. Strategies for detection of Plasmodium species gametocytes. PLoS ONE. 2013;
8:e76316. [PubMed: 24312682]
72. Tiono AB, et al. Dynamics of malaria transmission and susceptibility to clinical malaria episodes
following treatment of Plasmodium falciparum asymptomatic carriers: results of a cluster-
randomized study of community-wide screening and treatment, and a parallel entomology study.
BMC Infect Dis. 2013; 13:535. [PubMed: 24215306]
73. Okell LC, et al. The potential contribution of mass treatment to the control of Plasmodium
falciparum malaria. PLoS ONE. 2011; 6:e20179. [PubMed: 21629651]
74. WHO. Global malaria control and elimination: report of a technical review. WHO; 2008. at <http://
www.who.int/malaria/publications/atoz/9789241596756/en/>
75. White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malaria Journal.
2011; 10:297. [PubMed: 21989376]
76. Mueller I, et al. Natural acquisition of immunity to Plasmodium vivax: epidemiological
observations and potential targets. Adv Parasitol. 2013; 81:77–131. [PubMed: 23384622]
77. Betuela I, et al. Relapses contribute significantly to the risk of Plasmodium vivax infection and
disease in Papua New Guinean children 1–5 years of age. J Infect Dis. 2012; 206:1771–1780.
[PubMed: 22966124]
78. Kaneko A, et al. Malaria eradication on islands. Lancet. 2000; 356:1560–1564. [PubMed:
11075770]
79. Hsiang MS, et al. Mass drug administration for the control and elimination of Plasmodium vivax
malaria: an ecological study from Jiangsu province, China. Malar J. 2013; 12:383. [PubMed:
24175930]
80. Wells TNC, et al. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to
malaria elimination. Trends Parasitol. 2010; 26:145–151. [PubMed: 20133198]
Lin et al. Page 15























• Persons with asymptomatic malaria are an important reservoir of transmission.
• Smear-positive asymptomatics are more infectious to mosquitoes than those
with submicroscopic infection.
• Current efforts to eliminate the malaria reservoir often target those with
submicroscopic malaria.
• The contribution of submicroscopic malaria to transmission needs further
evaluation.
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Figure 1. Submicroscopic gametocytemia and the mosquito infectivity threshold
Mosquito feeding assays, whereby Anopheles mosquitoes are fed blood-stage parasites,
either by direct skin feeding or via a membrane feeding apparatus, and subsequently
dissected to look for malaria parasites, represent the standard way of assessing human-to-
mosquito infectious potential [33,34,35,36]. Depicted are approximate curves of human-to-
mosquito infectivity as a function of density of gametocytes in the circulating blood drawn
from data depicting natural human malaria infections in West Africa (blue) [39,40] and
children post-treatment in Burkina Faso and Kenya (red) [41]. While the range of the older
series is much greater, both demonstrate that the probability of mosquito infection is very
low until gametocyte densities well within the range of parasitemia detectable by
microscopy.
Lin et al. Page 17
Trends Parasitol. Author manuscript; available in PMC 2015 April 01.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
